{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Glaukos Corp. technically bullish or bearish?
As of October 31, 2025, Glaukos Corp. is in a mildly bearish trend, with mixed technical indicators and significant underperformance against the S&P 500 year-to-date and over the past year, although it has outperformed the benchmark over the last three years.
Is Glaukos Corp. technically bullish or bearish?
As of October 31, 2025, Glaukos Corp. shows a mildly bearish trend with mixed technical indicators, outperforming the S&P 500 recently but underperforming year-to-date, suggesting caution in the current market.
Is Glaukos Corp. technically bullish or bearish?
As of October 31, 2025, Glaukos Corp. is in a mildly bearish trend, with mixed technical indicators and a year-to-date return of -41.26%, significantly underperforming the S&P 500's 16.30%.
Glaukos Corp. Hits Day High with 13.89% Surge in Strong Intraday Performance
Glaukos Corp. has seen a notable increase in stock performance, achieving a significant intraday high on October 30, 2025. Despite recent challenges, including declines over the past year and year-to-date, the company has shown resilience with a substantial increase over the past three years and strong institutional backing.
Glaukos Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics
Glaukos Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has seen its stock price rise slightly to $83.09 amid a challenging year, with a return of -44.58%. The company faces mixed technical indicators and significant volatility, with a 52-week range between $77.10 and $163.71.
Is Glaukos Corp. technically bullish or bearish?
As of October 10, 2025, Glaukos Corp. is in a bearish trend, indicated by bearish signals from the weekly MACD and Bollinger Bands, despite a bullish monthly RSI, and has significantly underperformed the S&P 500, down 44.58% year-to-date compared to the S&P's 11.41% gain.
Is Glaukos Corp. technically bullish or bearish?
As of October 10, 2025, Glaukos Corp. is in a bearish trend, indicated by a bearish MACD, Bollinger Bands, and moving averages, with a year-to-date return of -44.94% compared to the S&P 500's 11.41%.
Is Glaukos Corp. technically bullish or bearish?
As of October 10, 2025, Glaukos Corp. is in a bearish trend with weak strength indicators, underperforming the S&P 500 significantly with a year-to-date return of -44.94%.
Glaukos Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics
Glaukos Corp., a small-cap biotechnology firm, has seen notable stock price fluctuations, currently at $86.62. Over the past year, it reached a high of $163.71 and a low of $77.10. The company's performance has been mixed compared to the S&P 500, with significant volatility and challenges in the market.
Is Glaukos Corp. technically bullish or bearish?
As of October 3, 2025, Glaukos Corp. is in a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 with returns of -7.79% over the past month and -33.87% over the past year.
Is Glaukos Corp. technically bullish or bearish?
As of October 3, 2025, Glaukos Corp. shows a mildly bearish trend with mixed technical indicators and has significantly underperformed the S&P 500, posting a year-to-date return of -41.70% compared to the S&P's 14.18%.
Is Glaukos Corp. technically bullish or bearish?
As of October 3, 2025, Glaukos Corp. has a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -41.70% versus the S&P's 14.18%.
Is Glaukos Corp. technically bullish or bearish?
As of September 12, 2025, Glaukos Corp. is in a bearish trend with moderate strength, indicated by daily moving averages and weekly KST, while underperforming the S&P 500 with a year-to-date return of -42.75%.
Is Glaukos Corp. overvalued or undervalued?
As of May 7, 2020, Glaukos Corp. is considered overvalued and risky due to its high Price to Book Value of 6.96, negative EV to EBIT and EV to EBITDA ratios, low ROCE and ROE, and poor stock performance compared to its peers and the S&P 500.
Glaukos Corp. Experiences Revision in Stock Evaluation Amid Market Challenges
Glaukos Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has faced significant challenges, with a one-year return of -36.14%. Despite recent price fluctuations and bearish market indicators, the company has shown resilience over longer periods, achieving notable returns of 41.87% over three years and 63.11% over five years.
Is Glaukos Corp. overvalued or undervalued?
As of May 7, 2020, Glaukos Corp. is considered risky and overvalued due to its negative P/E ratio and poor financial metrics, including a Price to Book Value of 6.96, and a disappointing year-to-date return of -35.44%, significantly underperforming the S&P 500.
Is Glaukos Corp. technically bullish or bearish?
As of June 6, 2025, Glaukos Corp. is in a mildly bearish trend, influenced by daily moving averages and Bollinger Bands, despite some mildly bullish signals from weekly MACD and KST, leading to a cautious overall sentiment.
Who are in the management team of Glaukos Corp.?
As of March 2022, Glaukos Corp.'s management team includes Dr. William Link (Independent Chairman), Mr. Thomas Burns (President and CEO), and several independent directors: Dr. Gilbert Kliman, Mr. Mark Foley, Mr. David Hoffmeister, Mr. Marc Stapley, and Ms. Aimee Weisner. This team provides governance and strategic direction for the company.
What does Glaukos Corp. do?
Glaukos Corporation is an ophthalmic medical technology company specializing in glaucoma treatments, with recent net sales of $107 million and a market cap of approximately $5.7 billion. The company is currently operating at a loss, with a net profit of -$18 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
